Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abcellera Biologics Inc
(NQ:
ABCL
)
2.610
+0.100 (+3.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abcellera Biologics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
August 20, 2024
Via
Benzinga
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
August 14, 2024
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...
Via
Talk Markets
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
August 07, 2024
ABCL earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AbCellera Reports Q2 2024 Business Results
August 06, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
July 31, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
July 30, 2024
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.
Via
Talk Markets
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday
July 28, 2024
A week ago it was suggested that the AI/semiconductor stocks sector was oversold. The decline bottomed on Wednesday and by the close of business this past Friday the sector had rebounded nicely almost...
Via
Talk Markets
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Via
The Motley Fool
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
July 18, 2024
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under...
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
July 02, 2024
Although fraught with risk, these biotech exposures bring enormous upside potential.
Via
Talk Markets
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
June 25, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
June 17, 2024
The global
Via
Talk Markets
Down 57%, Is AbCellera Biologics a Buy on the Dip?
June 13, 2024
Wall Street analysts say this drug developer can more than double your money.
Via
The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
June 10, 2024
The global
Via
Talk Markets
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
May 28, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...
Via
Talk Markets
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
May 20, 2024
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
3 Stock Gems Hiding in the Nasdaq
May 13, 2024
If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks.
Via
InvestorPlace
5 Of 7 AI Categories Rose, Slightly,Over Past Week
May 11, 2024
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
May 08, 2024
ABCL earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
AbCellera Reports Q1 2024 Business Results
May 07, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
May 01, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
April 23, 2024
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...
Via
Talk Markets
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
April 15, 2024
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
April 08, 2024
From
AbCellera Biologics Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.